Ivermectin, a drug that has been prescribed for human parasites since 1988, can significantly improve survival rates of COVID-19, the American Journal of Therapeutics has reported in their July/August 2021 issue.
That conclusion is based on an analysis of 24 trials, worldwide. The trials include both treatment and prevention testing.
“Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin,” AJT’s report notes.
“Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.”
The report says adverse effects of Ivermectin appear to be low, reporting that:
“The evidence on severe adverse events in this review was graded as low certainty, partly because there were too few events to reach statistical significance.
“Evidence from a recent systematic review of ivermectin use among people with parasitic infections suggests that ivermectin administered at the usual doses (0.2 or 0.4 mg/kg) is safe and could be safe at higher doses. A recent World Health Organization document on ivermectin use for scabies found that adverse events with ivermectin were primarily minor and transient.”
A prior AJT May 2021 review of Ivermectin trials also found “large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.”
“Furthermore,” per the May report, “results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin.”
The May AJT article concludes “the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.”
Ivermectin was first prescribed for the river blindness parasite Onchocerciasis in 1988, after prior use for animal parasites, per a February 2011 article titled “Ivermectin, ‘Wonder drug’ from Japan: the human use perspective,” authored by The Kitasato Institute, Tokyo, Japan, and posted on the National Institutes of Health’s U.S. National Library of Medicine site, LINKED HERE.
“There are few drugs that can seriously lay claim to the title of ‘Wonder drug’, penicillin and aspirin being two that have perhaps had greatest beneficial impact on the health and wellbeing of Mankind,” the article notes.
“But ivermectin can also be considered alongside those worthy contenders, based on its versatility, safety and the beneficial impact that it has had, and continues to have, worldwide—especially on hundreds of millions of the world’s poorest people.”
American Journal of Therapeutics covers pharmacological developments in cardiology, infectious disease, oncology, anesthesiology, nephrology, toxicology, and psychotropics. It features original articles on the latest therapeutic approaches as well as critical articles on the drug approval process and therapeutic reviews covering pharmacokinetics, regulatory affairs, pediatric clinical pharmacology, hypertension, metabolism, and drug delivery systems. It is published by Wolters Kluwer, a Dutch company that provides information, software solutions, and services for professionals in the health, tax and accounting, finance, risk and compliance, and legal sectors.